Chromoplexy and chromotripsis models for CRPC genomoic landscape.
Dependent and independent androgen receptor activity pathways in CRPC development.
No biomarker validated as a surrogate for overall survival in CRPC patients.
AR-V7 splice variant to predict resistance to abiraterone and enzalutamide in CRPC.
Only rational treatment sequencing can be currently advised for CRPC.